Evidence map›Paper›PMID 30499246›Full record

GuidelineArthritis & rheumatology (Hoboken, N.J.)2019

Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis.

Jasvinder A Singh, Gordon Guyatt, Alexis Ogdie, Dafna D Gladman, Chad Deal, Atul Deodhar, Maureen Dubreuil, Jonathan Dunham, M Elaine Husni, Sarah Kenny and 26 more

Registry-linked trialOpen access · bronzeAbstract readPractice Guideline
PubMed Full text at PMC Publisher
In one paragraph

Guideline in Arthritis & rheumatology (Hoboken, N.J.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07706530 (A Phase 2 Randomized, Double Blind, Clinical Trial), which is not on this map. Cited by 217 papers, 17 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
217citing papers in PubMed, 17 pooled it
41.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07706530 phase2not yet recruitingnot on this mapstarted 2026, after this paper: background citation

A Phase 2 Randomized, Double Blind, Clinical Trial (RCT) to Assess the Efficacy, Safety, and Tolerability of Oral CBP-0276 200mg QD, 800mg QD or Placebo for CBP-0276, Administered to Adults With Active Psoriatic Arthritis (PsA).

TypeinterventionalSponsorClarent Biopharma, Inc.Ran2026 to 2027Enrolled240ConditionsArthritic PsoriasisArmsCBP-0276 capsules 100mg, Placebo
3 · Its place in the literature

Who cites it

217 citing papers in PubMed, 17 syntheses or guidelines pooled it, 471 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. La Tunisie medicale · 2025
    Guideline
  4. Pooled it
  5. Pooled it
  6. Guideline
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Brazilian Society of Rheumatology 2020 guidelines for psoriatic arthritis.Advances in rheumatology (London, England) · 2021
    Pooled it
  12. Guideline
  13. Pooled it
  14. Guideline
  15. Pooled it
  16. Guideline
  17. Guideline
  18. Trial
  19. Trial
  20. Trial

157 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

36 authors at 20 institutions in 3 countries.

Jasvinder A SinghUniversity of Alabama at Birmingham and Birmingham Veterans Affairs Medical Center, Birmingham, Alabama.ORCID 0000-0003-3485-0006
Gordon GuyattMcMaster University, Hamilton, Ontario, Canada.
Alexis OgdieUniversity of Pennsylvania, Philadelphia.
Dafna D GladmanUniversity of Toronto and Toronto Western Hospital, Toronto, Ontario, Canada.
Chad DealCleveland Clinic, Cleveland, Ohio.
Atul DeodharOregon Health & Science University, Portland.
Maureen DubreuilBoston Medical Center, Boston, Massachusetts.
Jonathan DunhamUniversity of Pennsylvania, Philadelphia.
M Elaine HusniCleveland Clinic, Cleveland, Ohio.
Sarah KennyNew York, New York.
Jennifer Kwan-MorleyPremier Orthopaedics, Malvern, Pennsylvania.
Janice LinStanford University, Stanford, California.
Paula MarchettaConcorde Medical Group, New York, New York.
Philip J MeaseSwedish-Providence Health Systems and University of Washington, Seattle, Washington.
Joseph F MerolaBrigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Julie MinerComprehensive Therapy Consultants and Therapy Steps, Roswell, Georgia.
Christopher T RitchlinUniversity of Rochester Medical Center, Rochester, New York.
Bernadette SiatonUniversity of Maryland School of Medicine, Baltimore.
Benjamin J SmithFlorida State University College of Medicine School of Physician Assistant Practice, Tallahassee.
Abby S Van VoorheesEastern Virginia Medical School, Norfolk.
Anna Helena JonssonBrigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Amit Aakash ShahAmerican College of Rheumatology, Atlanta, Georgia.
Nancy SullivanECRI Institute, Plymouth Meeting, Pennsylvania.
Marat TurgunbaevAmerican College of Rheumatology, Atlanta, Georgia.
Laura C CoatesUniversity of Oxford, Oxford, UK.
Alice GottliebNew York Medical College at Metropolitan Hospital, New York, New York.
Marina MagreyCase Western/MetroHealth, Cleveland, Ohio.
W Benjamin NowellGlobal Healthy Living Foundation, Nyack, New York.
Ana-Maria OrbaiJohns Hopkins University, Baltimore, Maryland.
Soumya M ReddyNew York University School of Medicine, New York, New York.
Jose U ScherNew York University School of Medicine, New York, New York.
Evan SiegelArthritis & Rheumatism Associates, Rockville, Maryland.
Michael SiegelNational Psoriasis Foundation, Portland, Oregon.
Jessica A WalshUniversity of Utah and George E. Wahlen VeteranS Affairs Medical Center, Salt Lake City, Utah.
Amy S TurnerAmerican College of Rheumatology, Atlanta, Georgia.
James RestonECRI Institute, Plymouth Meeting, Pennsylvania.
American College of Rheumatology · USBrigham and Women's Hospital · USCleveland Clinic · USECRI Institute · USNew York University · USUniversity of Pennsylvania · USArthritis and Rheumatism Associates · USBoston Medical Center · USCompass Technology Group (United States) · USConcordia College - New York · USEastern Virginia Medical School · USFlorida State University · USGlobal Healthy Living Foundation · USJohns Hopkins University · USMcMaster University · CAMetroHealth · USNational Psoriasis Foundation · USNew York Medical College · USNew York Proton Center · USOregon Health & Science University · US

Funding

Establishing the Value of Treatment Strategies in SpondyloarthritisK23AR069127 · NIAMS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI DUBREUIL, MAUREEN · 2016 to 2020
$848k
American College of RheumatologyDepartment of Health CS-2016-16-016National Psoriasis FoundationNIAMS NIH HHS K23 AR069127
6 · The paper itself

Abstract

objectiveTo develop an evidence-based guideline for the pharmacologic and nonpharmacologic treatment of psoriatic arthritis (PsA), as a collaboration between the American College of Rheumatology (ACR) and the National Psoriasis Foundation (NPF).

methodsWe identified critical outcomes in PsA and clinically relevant PICO (population/intervention/comparator/outcomes) questions. A Literature Review Team performed a systematic literature review to summarize evidence supporting the benefits and harms of available pharmacologic and nonpharmacologic therapies for PsA. GRADE (Grading of Recommendations Assessment, Development and Evaluation) methodology was used to rate the quality of the evidence. A voting panel, including rheumatologists, dermatologists, other health professionals, and patients, achieved consensus on the direction and the strength of the recommendations.

resultsThe guideline covers the management of active PsA in patients who are treatment-naive and those who continue to have active PsA despite treatment, and addresses the use of oral small molecules, tumor necrosis factor inhibitors, interleukin-12/23 inhibitors (IL-12/23i), IL-17 inhibitors, CTLA4-Ig (abatacept), and a JAK inhibitor (tofacitinib). We also developed recommendations for psoriatic spondylitis, predominant enthesitis, and treatment in the presence of concomitant inflammatory bowel disease, diabetes, or serious infections. We formulated recommendations for a treat-to-target strategy, vaccinations, and nonpharmacologic therapies. Six percent of the recommendations were strong and 94% conditional, indicating the importance of active discussion between the health care provider and the patient to choose the optimal treatment.

conclusionThe 2018 ACR/NPF PsA guideline serves as a tool for health care providers and patients in the selection of appropriate therapy in common clinical scenarios. Best treatment decisions consider each individual patient situation. The guideline is not meant to be proscriptive and should not be used to limit treatment options for patients with PsA.

Indexed as

Physical Therapy ModalitiesAbataceptAdalimumabAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAnti-Inflammatory Agents, Non-SteroidalAntirheumatic AgentsArthritis, PsoriaticComorbidityDiabetes MellitusEnthesopathyEtanerceptEvidence-Based MedicineExerciseGlucocorticoidsHumansAbataceptAdalimumabAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAnti-Inflammatory Agents, Non-SteroidalAntirheumatic AgentsEtanerceptGlucocorticoidsgolimumabImmunosuppressive AgentsInfliximabInterleukin-12Interleukin-17Interleukin-23ixekizumabPiperidinesPyrimidinesPyrrolessecukinumabtofacitinibTumor Necrosis Factor-alphaUstekinumab

Identifiers

PMID30499246
PMCPMC8218333
OpenAlexW2901986848

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.